...
TBPHSMALL

Theravance Biopharma, Inc.

HealthcareBiotechnology
$18.25
$0.00(+0.33%)
52W$7.90
$21.03
FinancialsValuationvs UTHR
Updated Mar 2, 12:00 AM
RSI38
RS Rating79/99
Beta0.50
Volatility47%
F-Score4/9
Mkt Cap$925M
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Theravance Biopharma, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is moderate (RS Rating: 79), indicating performance broadly in line with the market. Earnings growth of 127% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.

Relative Strength
79
out of 99
Average
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
0.50
vs S&P 500
LOW VOL
52W Position
79%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$19.33
50 SMA > 100 SMA$17.85
100 SMA > 150 SMA$16.32
150 SMA > 200 SMA$14.89

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$19.41-5.99%BELOW
50 SMA$19.33-5.61%BELOW
100 SMA$17.85+2.25%ABOVE
150 SMA$16.32+11.85%ABOVE
200 SMA$14.89+22.56%ABOVE

Price Performance

1D+0.3%
1W-5.2%
1M-4.1%
3M-10.1%
6M+30.6%
YTD+0.6%
1Y+95.2%
3Y+19.1%
52-Week Trading Range79% from low
$18.25
52W Low$7.90
52W High$21.03

Technical Indicators

RSI (14)BEARISH
37.5
305070
VCP ScoreCOOL
5/10
Base depth: 20.7%

Risk Profile

Beta
0.50
52W Vol
47%
ATR
$0.84
Max DD (1Y)
-19%

Volume Analysis

Today
18
50D Avg
330.8K
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q4'24-82%
$-0.31
Q1'25-13%
$-0.27
Q2'25+418%
$1.08
Q3'25+127%
$0.07
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+18.60%
5 Years:-2.59%
3 Years:+5.19%
TTM:+27.12%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+156.44%

Stock Price CAGR

10 Years:+1.50%
5 Years:+0.87%
3 Years:+19.11%
1 Year:+95.19%

Return on Equity

10Y Avg:101.5%
5Y Avg:547.9%
3Y Avg:547.9%
Last Year:12.6%

Key Metrics

Market Cap$925M
Gross Margin1.0%
Net Margin-87.6%
Piotroski F-Score4/9

More TBPH Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

TBPH vs UTHRUTHRZLABAMRNALKS

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 79 meansTBPH outperformed 79% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.50 means 50% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 4/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 5/10 with COOL status.

Frequently Asked Questions

Is TBPH in an uptrend right now?

TBPH has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is TBPH overbought or oversold?

TBPH's RSI (14) is 38. The stock is in neutral territory, neither overbought nor oversold.

Is TBPH outperforming the market?

TBPH has a Relative Strength (RS) Rating of 79 out of 99. TBPH is performing about average compared to the market.

Where is TBPH in its 52-week range?

TBPH is trading at $18.25, which is 87% of its 52-week high ($21.03) and 79% above its 52-week low ($7.90).

How volatile is TBPH?

TBPH has a Beta of 0.50 and 52-week volatility of 47%. It's less volatile than the S&P 500 - generally more stable.